Synergy between Raf and BCL2 in abrogating the cytokine dependency of hematopoietic cells

Leukemia

Volumn 14, Issue 6, 2000, Pages 1060-1079

  Moye, P W ^a   Blalock, W L ^a   Hoyle, P E ^a   Chang, F ^a   Franklin, R A ^a   Weinstein Oppenheimer, C ^a,b   Pearce, M ^a   Steelman, L ^a   McMahon, M ^c   McCubrey, J A ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b UNIVERSIDAD DE VALPARAÍSO   (Chile)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; BCL2; Cytokine dependency; Raf

Indexed keywords

CHIMERIC PROTEIN; CYTOKINE; ESTRADIOL; ESTROGEN RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN BCL 2; PROTEIN KINASE; RAF PROTEIN; RECEPTOR BLOCKING AGENT; TAMOXIFEN; VIRUS VECTOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL GROWTH; CELL LINE; CELL PROTECTION; CONTROLLED STUDY; HEMATOPOIETIC CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; RETROVIRUS; VIRUS INFECTION;

EID: 0034120633     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401792     Document Type: Article

References (67)

1. Blalock WL, Weinstein-Oppenheimer C, Chang F, Hoyle PE, Wang XY, Algate PA, Franklin RA, Oberhaus SM, Steelman LS, McCubrey JA. Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-.3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. Leukemia 1999; 13: 1109-1166.
2. Wang XY, Steelman LS, McCubrey JA. Abnormal activation of cytokine gene expression by intracisternal type A particle transposition: effects of mutations which result in autocrine growth factor stimulation and malignant transformation. Cytokin Cell Mol Ther 1997; 3: 3-19.
3. Lotem J, Sachs L. Control of apoptosis in hematopoiesis and leukemia by cytokines, tumor suppressor and oncogenes. Leukemia 1996; 10: 925-931.
4. Wang XY, McCubrey J. Regulation of interleukin 3 expression in normal and autocrine transformed hematopoietic cells. Int J Oncol 1997; 10: 989-1001.
5. Algate PA, Steelman LS, Mayo MW, Miyajima A, McCubrey JA. Regulation of the interleukin-3 (IL-3) receptor by IL-3 in the fetal liver-derived FL5.12 cell line. Blood 1994; 83: 2450-2468.
6. Steelman LS, Algate PA, Blalock WL, Wang XY, Prevost KD, Hoyle PE, McCubrey JA. Oncogenic effects of overexpression of the interleukin-3 receptor on hematopoietic cells. Leukemia 1996; 10: 528-542.
7. Miyajima A, Kitamura T, Harada N, Yokota T, Arai K-L. Cytokine receptors and signal transduction. Annu Rev Immunol 1992; 10: 295-331.
8. Kinoshita T, Yokata T, Arai K, Miyajima A. Suppression of apoptotic death in hematopoietic cells by signalling through the IL-3/GM-CSF receptors. EMBO J 1995; 14: 265-275.
9. Dexter TM, Garland J, Scott D, Scolnick E, Metcalf D. Growth factor-dependent hemopoietic precursor cell lines. J Exp Med 1980; 152: 1036-1047.
10. McKearn JP, McCubrey JA, Fagg B. Enrichment of hematopoietic precursor cells and cloning of multipotential B lymphocyte precursors. Proc Natl Acad Sci USA 1985; 82: 7414-7418.
11. McCubrey JA, Holland G, McKearn J, Risser R. Abrogation of factor-dependence in two IL-3-dependent cell lines can occur by two distinct mechanisms. Oncogene Res 1989; 4: 97-109.
12. McCubrey JA, Smith SR, Algate PA, deVente JE, White MK, Steelman LS. Retroviral infection can abrogate the factor-dependency of hematopoietic cells by autocrine and non-autocrine mechanisms depending on the presence of a functional viral oncogene. Oncogene 1993; 8: 2905-2915.
13. McCubrey JA, Steelman LS, Wang XY, Algate PA, Hoyle PE, White C, Davidian EW, Prevost KD, Robbins P, Mylott D, White MK. Differential effects of viral and cellular oncogenes on the growth factor-dependency of hematopoietic cells. Int J Oncol 1995; 7: 285-310.
14. Kitamura T, Sato M, Arai K-I, Miyajima A. Expression cloning of the human IL-3 receptor cDNA reveals a shared β subunit of the human IL-3 and GM-CSF receptors. Cell 1991; 66: 1165-1174.
15. McCubrey JA, May WS, Duronio V, Mufson A. Serine/threonine phosphorylation in cytokine signal transduction. Leukemia 2000; 14: 9-21.
16. McCubrey JA, Steelman LS, Hoyle PA, Blalock WL, Weinstein-Oppenheimer CR, Franklin RA, Cherwinski H, Bosch E, McMahon M. Differential abilities of activated Raf oncoproteins to abrogate cytokine dependency, prevent apoptosis and induce autocrine growth factor synthesis in human hematopoietic cells. Leukemia 1998; 12: 1903-1929.
17. Sakatsume M, Stancato LF, David M, Silvennoinen O, Saharinen P, Pierce I, Larner AC, Finbloom DS. Interferon gamma activation of Raf-1 is Jakl-dependent and p21ras-independent. J Biol Chem 1998; 273: 3021-3026.
18. Stancato LF, Sakatsume M, David M, Dent P, Dong F, Petricoin EF, Krolewski JJ, Silvennoinen O, Saharinen P, Pierce J, Marshall CJ, Sturgill T, Finbloom DS, Larner AC. Beta Interferon and oncostatin M activate Raf-1 and mitogen-activated protein kinase through a JAK1-dependent pathway. Mol Cell Biol, 1997; 17: 3833-3840.
19. Morrison D. Mechanisms regulating Raf-1 activity in signal transduction pathways. Mol Repro Dev 1995; 42: 507-514.
20. Dent P, Wu J, Romero G, Vincent LA, Castle D, Sturgill TW. Activation of the mitogen-activated protein kinase pathway in Triton X-100 disrupted NIH-3T3 cells by p21 ras and in vitro by plasma membranes from NIH3T3 cells. Mol Biol Cell 1993; 4: 83-493.
21. Dent P, Chow YH, Wu J, Morrison DK, love R, Sturgill TW. Expression, purification and characterization of recombinant mitogen-activated protein kinase kinases. Biochem J, 1994; 303: 105-112.
22. Dent P, Reardon DB, Morrison DK, Sturgill TW. Regulation of Raf1 and Rat-1 mutants by Ras-dependent and Ras-independent mechanisms in vitro. Mol Cell Biol 1995; 15: 4125-4135.
23. Dent P, Jarvis WD, Birrer MJ, Fisher PB, Schmidt-Ullrich RK, Grant S. The roles of signaling by the p42/p44 mitogen-activated protein (MAP) kinase pathway: a potential route to radio- and chemosensitization of tumor cells resulting in the induction of apoptosis and loss of clonogenicity. Leukemia 1998; 12: 1843-1850.
24. Jelinek T, Dent P, Sturgill TW, Weber MJ. Ras-induced activation of Raf-1 is dependent on tyrosine phosphorylation. Mol Cell Biol 1996; 16: 1027-1034.
25. Sakamoto KM, Mignacca RC, Casson JC. Signal transduction by granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors. Recep Chann 1994; 2: 175-181.
26. Kwon EM, Sakamoto KM. The molecular mechanism of action of granulocyte-macrophage/colony-stimulating factor. J Invest Med 1996; 44: 442-446.
27. Lee HJ, Mignacca RC, Sakamoto KM. Transcriptional activation of egr-1 by granulocyte-macrophage colony-stimulating factor but not interleukin 3 requires phosphorylation of cAMP response element-binding protein (CREB) on serine 133. J Biol Chem 1995; 270: 15979-15983.
28. Wong A, Sakamoto KM. Granulocyte-macrophage colony-stimulating factor induces the transcriptional activation of egr-1 through a protein kinase A-independent signaling pathway. J Biol Chem 1995; 270: 30271-30273.
29. Watanabe S, Kubota H, Sakamoto KM, Arai K. Characterization of cis-acting sequences and trans-acting signals regulating early growth response 1 and c-fos promoters through the granulocyte-macrophage colony-stimulating factor receptor in BA/F3 cells. Blood 1997; 89: 1197-1206.
30. Mignacca RC, Lee HJ, Kwon EM, Sakamoto KM. Mechanism of transcriptional activation of the immediate early gene Egr-1 in response to PIXY321. Blood 1996; 88: 848-854.
31. Sakamoto KM, Fraser JK, Lee HJ, Lehman E, Gasson JC. Granulocyte-macrophage colony-stimultating factor and interleukin-3 signaling pathways converge on the CREB-binding site in the human egr-1 promoter. Mol Cell Biol 1994; 14: 5975-5985.
32. Samuels ML, Weber MJ, Bishop JM, McMahon M. Conditional transformation of cells and rapid activation of the mitogen-actvated protein kinase cascade by an estradiol-dependent human raf-1 protein kinase. Mol Cell Biol 1993; 13: 6241-6252.
33. Pritchard CA, Samuels ML, Bosch E, McMahon M. Conditionally oncogenic forms of the A-raf and B-raf protein kinases display different biological and biochemical properties in NIH 3T3 cells. Mol Cell Biol 1995; 15: 9430-9442.
34. Bosch E, Cherwinski H, Peterson D, McMahon M. Mutations of critical amino acids affect the biological and biochemical properties of oncogenic A-Raf and Raf-1. Oncogene 1997; 11: 1021-1034.
35. Blalock WL, Steelman LS, Pearce M, Franklin RA, McCarthy SA, Cherwinski H, McMahon M, McCubrey JA. A conditionally active form of MEK1 results in autocrine transformation in human and mouse hematopoietic cells. Oncogene 2000; 19: 526-536.
36. McCubrey JA, Steelman LS, Moye PW, Hoyle PE, Weinstein-Oppenheimer C, Chang F, Pierce M, White MK, Franklin R, Blalock WL. Effects of deregulated Raf and MEK1 expression on the cytokine dependency of hematopoietic cells. Actv Enzyme Regl 2000; 40 (in press).
37. Hoyle PE, Moye PW, Steelman LS, Blalock WL, Franklin RA, Pearce M, Cherwinski H, Bosch H, McMahon M, McCubrey JA. Differential abilities of the Raf family of protein of kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism. Leukemia 2000; 14: 642-656.
38. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 1996; 88: 306-401.
39. Kroemer G. The proto-oncogene Bcl-2 and its role in regulating apoptosis. Nature Med 1997; 3: 614-620.
40. 1 and Bcl-2, displaces Bax and promotes cell death. Cell 1995; 80: 285-291.
41. Young LS, Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene 1995; 11: 1217-1228.
42. Núnez G, London L, Hockenbery D, Alexander M, McKearn JP, Korsmeyer SJ. Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immnol 1990; 144: 3602-3610.
43. Sato N, Sakamaki K, Terada N, Arai K-J, Miyajima A. Signal transduction by the high-affinity GM-CSF receptor: two distinct cytoplasmic regions of the common β subunit responsible for different signaling. EMBO J 1993; 12: 4181-4189.
44. Ruvolo PP, Deng X, Ito T, Carr BK, May WS. Ceramide induces Bcl2 dephosphorylation via a mechanism involving mitochondrial PP2A. J Biol Chem 1999; 274: 20296-20300.
45. Ruvolo PP, Deng X, Carr BK, May WS. A functional role for mitochondrial protein kinase C alpha in Bcl2 phosphorylation and suppression of apoptosis. J Biol Chem 1998; 273: 25436-25442.
46. Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 1996; 87: 629-638.
47. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist Bad in response to survival factor results in binding to 14-3-3 not Bcl-xL. Cell 1996; 87: 619-628.
48. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997; 278: 687-689.
49. Ahmed NN, Grimes HL, Bellacosa A, Chan TO, Tsichlis PN. Transduction of interleukin-2 anti-apoptotic and proliferative signals via Akt protein kinase. Proc Natl Acad Sci USA 1997; 94: 3627-3632.
50. Srivastava RK, Srivastava AR, Korsmeyer SJ, Nesterova M, ChoChung YS, Longo DL. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol 1998; 18: 3509-3517.
51. Scheid MP, Duronio V. Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/akt: involvement of MEK upstream of Bad phosphorylation. Proc Natl Acad Sci USA 1998; 95: 7439-7444.
52. Haldar S, Basu A, Croce CM. Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. Cancer Res 1998; 58: 1609-1615.
53. Deng X, Ito T, Carr B, Mumby M, May WS. Reversible phosphorylation of Bcl-2 following IL-3 or byrostatin is mediated by interaction of PP2A. J Biol Chem 1998; 271: 34157-34163.
54. Blagosklonny MV, Schulte T, Nguyen P, Trepel J, Neckers LM. Taxol-induced apoptosis and phosphorylation of the Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 1996; 56: 1851-1854.
55. Blagosklonny MV, Chuman Y, Bergan RC, Fojo T. Mitogen-activated protein kinase pathway is dispensable for microtubule-active drug-induced Raf-1/Bcl-2 phosphorylation and apoptosis in leukemia cells. Leukemia 1999; 13: 1028-1036.
56. Hu ZB, Minden MD, McCulloch EA. Phosphorylation of Bcl-2 after exposure of human leukemic cells to retinoic acid. Blood 1998; 92: 1768-1775.
57. Rapp UR, Troppmair J, Carroll M, May WS. Role of raf-1 protein kinase in IL-3 and GM-CSF mediated signal transduction. Curr Top Microbiol Immunol 1990; 166: 129-139.
58. Cleveland JL, Troppmair J, Packham G, Askew DS, Lloyd P, Gonzalev-Garcia M, Nuñez G, Ihle JN, Rapp UR. v-raf suppresses apoptosis and promotes growth of interleukin-3-dependent myeloid cells. Oncogene 1994; 9: 2227-2233.
59. Wang HG, Miyashita T, Takayama S, Sato T, Torigoe T, Krajewski S, Tanaka S, Hovey L III, Troppmair J, Rapp UR, Reed JC. Apoptosis regulation by interaction of Bcl-2 and Raf-1 kinase. Oncogene 1994; 9: 2751-2756.
60. Wang HG, Takayama S, Rapp UR, Reed JC. Bcl-2 interacting protein, Bag-1 binds to and activates the kinase Raf-1. Proc Natl Acid Sci USA 1996; 93: 7063-7068.
61. Wang HG, Rapp UR, Reed JC. Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 1996; 87: 629-638.
62. Srivastava RK, Mi QS, Hardwick JM, Longo DL. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. Proc Nat Acad Sci USA 1999; 96: 3775-3780.
63. Dudley DT, Pung L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinases cascade. Proc Natl Acad Sci USA 1995; 92: 7686-7689.
64. Pumiglia KM, Decker SJ. Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc Natl Acad Sci USA 1997; 94: 448-452.
65. Gp1. Mol Cell Biol 1997; 17: 5598-5611.
66. Miller AD, Rosman CJ. Improved retroviral vectors for gene transfer and expression. Biotechniques 1989; 7: 900-990.
67. Lloyd AC, Obermuller F, Staddon S, Barth CF, McMahon M, Land H. Cooperating oncogenes converge to regulate cyclin/cdx complexes. Genes Dev 1997; 11: 663-667.